These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24445914)

  • 1. Should we give metformin to all men with CRPC?
    Clyne M
    Nat Rev Urol; 2014 Feb; 11(2):63. PubMed ID: 24445914
    [No Abstract]   [Full Text] [Related]  

  • 2. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
    Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
    Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
    Mayer MJ; Klotz LH; Venkateswaran V
    J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks.
    Hamilton RJ
    Eur Urol; 2014 Sep; 66(3):475-7; discussion 477-8. PubMed ID: 24472709
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies.
    Abdel-Rahman O
    Clin Genitourin Cancer; 2019 Feb; 17(1):e104-e112. PubMed ID: 30341029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
    Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
    Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
    Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
    Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
    Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
    Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
    Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy for CRPC].
    Ozono S; Furuse H
    Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
    Chen L; Ahmad N; Liu X
    Cell Cycle; 2016; 15(6):840-9. PubMed ID: 26900800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
    Mark M; Klingbiel D; Mey U; Winterhalder R; Rothermundt C; Gillessen S; von Moos R; Pollak M; Manetsch G; Strebel R; Cathomas R
    Clin Genitourin Cancer; 2019 Apr; 17(2):e323-e328. PubMed ID: 30686756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide: A Review in Castration-Resistant Prostate Cancer.
    Scott LJ
    Drugs; 2018 Dec; 78(18):1913-1924. PubMed ID: 30535926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Updated treatment of castration-resistant prostate cancer].
    Xu S; Zhang ZY
    Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer.
    Hu J; Aprikian AG; Vanhuyse M; Dragomir A
    J Oncol Pract; 2019 Jun; 15(6):e510-e519. PubMed ID: 31107628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis.
    Liang X; Hu K; Li D; Wang Y; Liu M; Wang X; Zhu W; Wang X; Yang Z; Lu J
    DNA Cell Biol; 2020 May; 39(5):836-847. PubMed ID: 32101033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
    Sternberg CN
    Future Oncol; 2019 May; 15(13):1437-1457. PubMed ID: 30848157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
    Nguyen HG; Yang JC; Kung HJ; Shi XB; Tilki D; Lara PN; DeVere White RW; Gao AC; Evans CP
    Oncogene; 2014 Sep; 33(36):4521-30. PubMed ID: 24662833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The success of therapies for metastatic CRPC continues.
    Shore ND
    Oncology (Williston Park); 2013 Nov; 27(11):1160-1. PubMed ID: 24575545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.